Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Israel-based Pluristem Therapeutics Inc. (PSTI - Snapshot Report) recently reported progress on its phase I/II clinical trial, which is evaluating the safety and efficacy of its PLacental eXpanded (PLX) cells in the treatment of muscle injury.

Pluristem develops placenta-based cell therapies. The cells from placenta are derived using the company’s proprietary PluriX therapy.

Safety is the primary endpoint of the study while the secondary endpoint is the gluteal muscle function after six months.

A positive outcome from this study will enable Pluristem to further evaluate the potential of PLX cells for this indication along with other non-surgical injuries such as sports injuries.

Pluristem develops and manufactures cell therapy products in collaboration with companies like United Therapeutics or through research and clinical institutions.

Pluristem intends to develop and produce cell therapy products for the treatment of multiple disorders using several methods of administration.

We note that Pluristem and its partner United Therapeutics (UTHR - Analyst Report) entered into a licensing agreement in Jun 2011 as per which United Therapeutics develops, markets and sells Pluristem's PLX cells for  pulmonary arterial hypertension (PAH).

Both the companies commenced a phase I study in Australia using Pluristem's PLX cells following favorable preclinical studies in Feb 2013.

In a significant development in Feb 2013, the US Food and Drug Administration (FDA) granted Pluristem's PLX cells an orphan drug status for the treatment of aplastic anemia.

Meanwhile, Celgene Corporation (CELG - Analyst Report) is also carrying out research on stem cells derived from the human placenta as well as from the umbilical cord for the treatment of different diseases.

Pluristem carries a Zacks Rank #3 (Hold). Pharma stocks, such as Array Biopharma (ARRY - Snapshot Report) currently appear to be attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%